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he opening of the panama canal in 1914 initiated an era in
 
which efforts to control malaria were aimed at the anopheline mosquito. The
World Health Organization’s Global Malaria Eradication Campaign in the
1950s and 1960s marked the apex of these efforts. The use of dichlorodiphenyltrichlo-
roethane (DDT) rid vast areas of endemic malaria virtually everywhere except in sub-
Saharan Africa. The eradication strategy was abandoned in 1969, because it came to be
considered logistically, socially, and politically impractical, especially given public con-
cern about the effects of DDT on the environment. It took two decades and a global re-
surgence of malaria before a new strategy emerged, one that was focused on treatment
rather than prevention.
 
1
 
 This treatment strategy is currently being debated, and its ef-
ficacy is unproved.
 
2,3
 
Both the broad collapse of preventive efforts and the waning efficacy of standard an-
timalarial drugs
 
4,5
 
 account for the global resurgence of malaria. New therapies are avail-
able, but the use of older drugs persists for social, economic, and clinical reasons, despite
resistance of the organisms to the older drugs. Efforts to use new antimalarial drugs may
be hampered by regulatory requirements or economic obstacles as well as by important
questions about safety for the large numbers of patients who treat themselves. Public
health agencies continue to support the distribution of older therapies, despite strong
criticism from scientists conducting research on the disease and its treatment and pre-
vention.
 
6
 
In addition to inadequate drug efficacy, new therapies may fail because of inap-
propriate use, inadequate absorption, poor adherence, contraindications, intolerabili-
ty, the use of counterfeit drugs or improper manufacture of drugs, or prohibitive cost.
Chloroquine and sulfadoxine–pyrimethamine, which for several decades were the
foundation of malaria therapy, had a low risk with respect to this array of problems.
However, the emergence and consolidation of resistance to these drugs eroded their
clinical usefulness.
The coccidian genus plasmodium contains 172 species that infect birds, reptiles, and
mammals. Four species infect humans — 
 
Plasmodium falciparum, P. malariae,
 
 
 
P. ovale,
 
and 
 
P. vivax
 
. 
 
P. falciparum
 
 and 
 
P. vivax 
 
account for the vast majority of the 300 million to
500 million infections that occur each year. Endemic transmission takes place in most
tropical latitudes and reaches into temperate zones seasonally (Fig. 1). Although each
type of infection causes debilitating febrile illness, only 
 
P. falciparum
 
 carries a substan-
tial risk of death; 1 million to 3 million deaths occur each year in regions of holoen-
demic infection in sub-Saharan Africa, most of them among infants and young children.
For plasmodia, humans are not the “definitive host,” a concept defined by parasitol-
ogists as the site where sexual recombination occurs. Instead, many species in the ge-
nus anopheles have that distinction. From the perspective of the parasite, humans are
t
plasmodia
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simply a means of getting into mosquitoes, where
sexual recombination can occur. A full description
of the extraordinary complexity of this cycle is be-
yond the scope of this review. Figure 2 illustrates the
essential features of the cycle and the terminology
of antimalarial therapies.
 
availability
 
Most developing nations license and make avail-
able only the antimalarial drugs that are provided
through national health programs.
 
7
 
 This approach
often excludes relatively expensive or risky thera-
pies, even for patients who may be able to afford a
given drug and have access to medical supervision.
The main factor affecting availability is economic
— the ability or inability to purchase a drug for
broad distribution and the potential reluctance to
use an agent because of an inability either to screen
users or to monitor its quality.
Chloroquine and sulfadoxine–pyrimethamine
cost less than 15 percent of the cost of the least ex-
pensive alternative agents and approximately 1 to
2 percent of the cost of many of the agents marketed
in the developed world (Table 1). The developing
world requires distribution strategies for effective
therapies that overcome the availability of cheap
but ineffective drugs. The U.S. National Academies
made a core recommendation
 
8
 
 that governments
and international financial institutions should com-
mit $300 million to $500 million per year within
five years to subsidize artemisinin-combined ther-
apies (an emerging family of antimalarial drugs,
including artemether, artesunate and dihydroar-
temisinin) to achieve prices for the end user in the
range of 10 to 20 cents. Unless this recommenda-
tion is followed, market forces will continue to drive
the use of ineffective therapies.
 
adherence
 
Most people taking antimalarial drugs live in rural
regions of the developing world and are not super-
vised by health professionals. A study conducted
among 1640 febrile patients with malaria in Burkina
Faso
 
9
 
 showed that 69 percent were self-treated, and
in a study in Ethiopia, among 630 febrile patients
with malaria, 67 percent were self-treated.
 
10
 
 Com-
plex, inconvenient, or poorly tolerated antimalarial
regimens carry a substantial risk of inadequate ad-
herence.
 
11
 
 Among 414 Brazilian patients, the risk of
extrinsic determinants 
of drug effectiveness
 
Figure 1. Risk of 
 
Plasmodium falciparum
 
 Malaria Worldwide.
 
Adapted from the Public Health Mapping Group, Communicable Diseases, World Health Organization, 
November 2002.
Mefloquine-resistant
Plasmodium falciparum
Malaria transmission
Limited risk
No malaria
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recurrent malaria correlated with self-reported poor
adherence,
 
12
 
 whereas among 632 Nigerian children
strict adherence correlated with clinical recovery.
 
13
 
Convenient and easily understood packaging and
education of the patients alleviate poor adherence.
Owing to lengthy and complex regimens, currently
used therapies such as quinine and primaquine and
new combined therapeutic strategies
 
14
 
 challenge
the ease of adherence.
 
counterfeit and substandard drugs
 
Counterfeit antimalarial drugs pose a serious threat
in regions where the trade in pharmaceuticals is not
rigorously regulated. A survey conducted in Came-
roon found insufficient or inactive ingredients in
38 percent of preparations labeled chloroquine, 78
percent of those labeled quinine, and 12 percent of
tablets labeled as an antifolate agent.
 
15
 
 A survey in
Southeast Asia involving 104 purchases of artesu-
nate tablets found that 38 percent of the tablets con-
tained no drug.
 
16
 
 The trade in counterfeit drugs un-
doubtedly results in many deaths, but it is lucrative
and carries little risk of imprisonment.
 
17
 
 The inad-
vertent marketing of substandard pharmaceuticals
poses another threat. In a survey of eight authorized
wholesalers in Tanzania selling combined sulfadox-
ine–pyrimethamine tablets, 11 percent of the tab-
lets failed industry standards for content, and 44
percent failed dissolution testing.
 
18
 
stage specificity
 
Plasmodia pass through distinct stages of form,
function, location, clinical consequence, and sus-
ceptibility to antimalarial drugs (Fig. 2 and Table 1).
Drug activity ranges from narrow (e.g., the activity
of quinine against asexual blood stages) to broad
(e.g., the activity of primaquine against sexual and
asexual forms in the blood and liver). Moreover, the
range of stage-specific susceptibility differs among
species of plasmodia — for example, chloroquine
kills the gametocytes of 
 
P. vivax
 
 but exerts no effect
against those of 
 
P. falciparum
 
. These intrinsic prop-
erties define the recommended uses of antimalari-
al drugs.
 
parasite burden
 
Most patients with malaria carry a burden of 10
 
8
 
 to
10
 
13
 
 parasites.
 
19
 
 Effective chemotherapy induces a
constant fractional decline with each asexual cy-
cle,
 
20
 
 at a rate that varies according to the suscepti-
bility of the parasite to a given drug. For example,
artemisinin derivatives induce reductions of 10
 
4
 
,
whereas tetracycline achieves a reduction by only a
factor of 10 with each cycle. The duration of expo-
sure to a drug that is needed to eliminate infection
hinges on the intrinsic rate of decline and, more im-
portant, on the initial parasite burden.
 
21
 
 High levels
of parasitemia, as compared with a low burden, re-
quire longer exposure to effective drug levels and
have a relatively higher risk of treatment failure.
 
22
 
pharmacokinetics
 
A variety of factors affect the pharmacokinetics of
antimalarial drugs. Variant alleles of the human
intrinsic determinants 
of drug effectiveness
 
Figure 2. Antimalarial Drug Activity in the Life Cycle of Plasmodia.
 
Tissue-stage schizonticides kill the asexual stages developing in the liver, in-
cluding liver schizonts (all species) and quiescent hypnozoites (
 
Plasmodium 
vivax
 
 and 
 
P. ovale
 
), thus preventing primary or secondary attacks (relapses) of 
clinical malaria. Blood-stage schizonticides interrupt asexual schizogony (mi-
totic division) in red cells, preventing or terminating clinical attacks of malar-
ia. Gametocytocides kill or sterilize sexual stages in the blood, thus prevent-
ing infection of mosquitoes and transmission of the disease. Another class of 
drugs, the sporontocides (which kill forms developing in the mosquito, in-
cluding the sporozoites that infect humans), is not represented here, because 
none are available for clinical use.
Blood
Liver
Blood
schizonticide
Tissue 
schizonticide
Gametocytocide
Hypnozoites
Schizonts
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gene for cytochrome P-450 2C19 (CYP2C19), for
example, correlate with slow or rapid metabolism
of some antimalarial agents. For example, chlo-
roguanide, metabolized through the activity of
CYP2C19, was studied in 126 healthy, unrelated Ni-
gerian subjects, of whom 5 percent had slow metab-
olism of the drug (8 percent of the normal rate).
 
23
 
A study of Thai subjects taking oral contraceptives
reported that metabolism of chloroguanide was de-
creased by 34 percent,
 
24
 
 a finding that may be ex-
plained by inhibition of CYP2C19 activity by estro-
gen. Certain foods may also profoundly affect the
bioavailability (and toxicity) of certain antimalarial
drugs — for example, fatty foods affect the bio-
availability of halofantrine and of the combination
of lumefantrine and artemether.
 
safety and tolerability
 
In rural health care centers, staff with relatively little
formal training may be responsible for taking care
of patients with malaria. The patients often have no
written medical history, and the centers have mini-
mal capacity for laboratory screening for contrain-
dications to particular medications. Worse still,
most of these people with malaria treat themselves
with antimalarial agents acquired over the counter
or passed from household to household.
Any antimalarial drugs that are to be distribut-
ed in such regions need to be safe and well toler-
ated, and the risks associated both with the indi-
cated use and with contraindicated or inappropriate
uses should be considered. Clinical studies support-
ing the licensing of new antimalarial drugs rarely
include highly vulnerable groups such as infants,
young children, and pregnant women.
 
25
 
 Thus, safe-
ty issues often drive the decision to continue distrib-
uting chloroquine or sulfadoxine–pyrimethamine,
despite substantial parasite resistance. Key data
with regard to the safety and tolerability of the most
commonly used antimalarial drugs are summarized
in Table 2.
 
immunity
 
The intersection of immunity to plasmodia and an-
timalarial drug activity is poorly understood. In a
study of Brazilian patients, self-reported poor ad-
herence correlated with a risk of recurrence among
nonimmune persons (i.e., those with a first infec-
tion) but not among semi-immune persons (i.e.,
those with >4.8 years’ exposure to plasmodia).
 
12
 
Among 80 Lao patients, the level of humoral im-
munity to 
 
P. falciparum
 
 and the risk of therapeutic
failure were correlated with the parasite count on
admission to the hospital and the length of time to
 
* Unless otherwise indicated, the cost shown is the cost, in 2003 U.S. dollars, of medication for one adult treatment regi-
men, purchased in bulk, according to the International Drug Price Indicator Guide (IDPIG) (http://erc.msh.org/
mainpage.cfm?file=1.0.htm&module=dmp&language=English).
† U.S. commercial sources were surveyed; the cost is not available from the IDPIG.
‡ The cost shown is from the IDPIG; the combination is available through the World Health Organization (WHO) to qual-
ified purchasers at a cost of $2.40 per adult treatment regimen.
§ The cost shown is from the WHO.
 
¶The cost shown is from Arrow et al.
 
8
 
Table 1. Cost, Convenience, and Primary Clinical Application of Antimalarial Therapies.
Therapy Cost ($)*
No. of 
Doses
Duration
of Therapy Application
 
Chloroquine 0.11 3 48 hr Blood-stage schizonticide
Sulfadoxine–pyrimethamine 0.14 1 Single dose Blood-stage schizonticide
Quinine 0.97 21 7 days Blood-stage schizonticide
Mefloquine 2.55 1 Single dose Blood-stage schizonticide
Atovaquone–chloroguanide 48.00† 3 48 hr Blood-stage schizonticide
Artemether–lumefantrine 9.12‡ 6 48 hr Blood-stage schizonticide, gametocytocide
Artesunate–mefloquine 5.00§ 6 48 hr Blood-stage schizonticide, gametocytocide
Artesunate–sulfadoxine–
pyrimethamine
2.40¶ 3 48 hr Blood-stage schizonticide, gametocytocide
Artesunate–amodiaquine 2.00¶ 3 48 hr Blood-stage schizonticide, gametocytocide
Primaquine 1.68 7–14 7 days–8 wk Tissue-stage schizonticide, gametocytocide
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the resolution of fever.
 
29
 
 Djimde et al.
 
30
 
 showed that
the clearance of 
 
P. falciparum
 
 organisms carrying a
mutant transporter gene,
 
 pfcrt 
 
K76T, that was linked
with resistance to chloroquine correlated with ac-
quired immunity in subjects in sub-Saharan Africa.
In subjects with relatively little immunity who were
infected with mutant parasites, the chloroquine
therapy failed more frequently than in those infect-
ed with the same genotype of 
 
P. falciparum
 
 organ-
isms who had clinical immunity. However, such cor-
relations do not directly link immune effectors with
drug activity; acquired immunity independently re-
duces the parasite burden, which is a well-known
determinant of antimalarial effectiveness.
The acquired immunity that occurs throughout
regions of holoendemic infection in sub-Saharan
Africa may explain the relatively late increase in re-
sistance in that region. Most people at risk in South
America and Asia lack immunity and consequently
carry substantially higher parasite burdens than do
most Africans. Moreover, their symptomatic infec-
tions are generally treated far more often than are
asymptomatic infections among Africans. In Asia
and South America, these factors substantially in-
crease the probability of the selection of resistant
genotypes.
 
14
 
resistance
 
The parasites causing malaria exhibit a range of sus-
ceptibility to antimalarial agents. Several distinct
phenomena explain this range, including species-
specific innate resistance (e.g., asexual blood stages
of 
 
P. falciparum
 
 lack susceptibility to primaquine,
whereas those of 
 
P. vivax
 
 appear to be sensitive to
it
 
31
 
); strain-specific innate resistance (e.g., that of
asexual liver stages of 
 
P. vivax
 
 from the island of New
Guinea against primaquine
 
32
 
); and acquired resis-
tance. Of these, acquired resistance is the most im-
portant, because failure may occur even in the pres-
ence of complete adherence to the recommended
therapies. Studies in Senegal suggest that resistance
to chloroquine contributed to an increase by a factor
of 2 to 11 in mortality from malaria.
 
33
 
 In western
Kenya, case fatality rates were markedly higher
among children receiving chloroquine than among
those receiving other therapies.
 
34
 
Most of the data on the responses of 
 
P. falcipa-
rum
 
 to therapy reflect this emphasis on acquired re-
sistance. Nonetheless, 
 
P. vivax
 
 profoundly affects
public health outside Africa,
 
35
 
 and data are also
available that cover its resistance to chloroquine.
 
P. malariae
 
 and 
 
P. ovale
 
 infect relatively few people,
and little is known about acquired resistance in these
 
* Data in the table are from Taylor and White,
 
25
 
 Centers for Disease Control and Prevention,
 
26
 
 Phillips-Howard and Wood,
 
27
 
 and Wernsdorfer.
 
28
 
 
 
G6PD denotes glucose-6-phosphate dehydrogenase, and QTc QT interval corrected for heart rate.
 
Table 2. Safety and Tolerability of Available Antimalarial Drugs.*
Drug Adverse Effects Contraindications Severe Adverse Events
 
Chloroquine Gastrointestinal upset, itching, 
dizziness
Epilepsy Death from overdose
Sulfadoxine–pyrimethamine — Pregnancy, renal disease Stevens–Johnson syndrome
Quinine Tinnitus, vertigo, headache, fever, 
syncope, delirium, nausea
G6PD deficiency, pregnancy, optic 
neuritis, tinnitus, thrombocytopenic 
purpura, blackwater fever
Hemolytic anemia, coma, 
respiratory arrest, renal 
failure
Mefloquine Vomiting, headache, insomnia, 
vivid dreams, anxiety, dizziness
Depression, schizophrenia, anxiety 
disorder, any psychosis, irregular 
heartbeat
Psychosis
Atovaquone–chloroguanide Gastrointestinal upset, headache, 
stomatitis
Weight of <11 kg in children, pregnancy, 
breast-feeding, renal impairment
None known
Artemether–lumefantrine Dizziness, palpitations Pregnancy, severe malaria Impaired hearing
Artesunate–mefloquine Vomiting, anorexia, diarrhea Depression, schizophrenia, anxiety 
disorder, any psychosis, irregular 
heartbeat
None known
Halofantrine Gastrointestinal upset, 
prolonged QTc
Conduction abnormalities, pregnancy, 
breast-feeding, infancy, use of 
mefloquine
Cardiac arrest
Primaquine Gastrointestinal upset, elevated 
levels of methemoglobin
Pregnancy, G6PD deficiency, 
breast-feeding
Hemolytic anemia
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species. Resistance to chloroquine in 
 
P. malariae
 
 was
reported from Indonesia
 
36
 
 but is apparently debat-
able.
 
37
 
Genetic mutations among strains of plasmodia
have been linked with phenotypes of clinical resis-
tance. Some studies challenge specific links between
genotype and phenotype in certain settings, but pu-
tative markers have emerged (Table 3); the exten-
sive literature on this topic has been reviewed.
 
38-43
 
Validated genetic determinants of resistance would
vastly improve surveillance and, thus, the effective-
ness of resources for the treatment and control of
malaria.
The risk of resistance varies according to species,
strain, and drug. Estimates of risk are often con-
founded by the determinants already described.
Methods of estimating risk also vary. The following
estimates of the risk of treatment failure were dis-
tilled from many studies and should not be con-
strued as quantitative region-specific risks, because
patterns of resistance vary tremendously, even with-
in nations. Protocols that evaluate efficacy generally
follow the guidelines of the World Health Organi-
zation, which recommend a follow-up period of
7, 14, or 28 days.
 
44
 
 The timing of recurrent para-
sitemia or disease reflects the degree of resistance
— earlier failure represents higher-grade resistance.
Late recurrence may be confounded by reinfection,
especially in regions of intense transmission. Inves-
tigators in sub-Saharan Africa thus favor an in vivo
test with a duration of 7 or 14 days, whereas those
in other regions tend to favor a 28-day test or even
63-day test. Comparison of genotypes of the strains
causing original and recurrent parasitemias can be
used to address confounding by reinfection, but rel-
atively few reporting clinics or laboratories have the
capacity to conduct such testing. Tests conducted
in Africa tend to report both parasitologic failure
(i.e., recurrent parasitemia after treatment, indepen-
dent of clinical presentation) and the clinical failure
of treatment, whereas investigators elsewhere focus
on parasitologic failure.
 
44
 
chloroquine
 
After an analogue that had been developed in Ger-
many was captured in 1943, during World War II,
chloroquine quickly came into universal use as ther-
apy for and prophylaxis against malaria.
 
45
 
 Chloro-
quine was highly effective, easily administered, and
inexpensive and had good safety and tolerability.
However, resistance in 
 
P. falciparum
 
 appeared in the
late 1950s in Thailand and Colombia and emerged
in the 1970s in New Guinea and eastern sub-Sahar-
an Africa. Today, resistance to chloroquine in malar-
ia caused by 
 
P. falciparum
 
 occurs everywhere except
in Central America (and Hispaniola) and in some re-
gions of southwestern Asia.
In sub-Saharan Africa, the risk of parasitologic
treatment failure with the use of chloroquine was
almost uniformly greater than 40 percent, whereas
the risk of clinical treatment failure tended to be
higher in the eastern and central portions of the Af-
rican continent (typically >30 percent and often >50
percent, respectively) than in the west (typically <20
percent).
 
8
 
 Elsewhere, the rates of parasitologic fail-
ure at day 28 were 57 percent (of 209 evaluations)
in southwestern Asia,
 
46-50
 
 46 percent (2280 evalu-
ations) in southern Asia,
 
51-57
 
 85 percent (223 eval-
uations) in Southeast Asia,
 
58-66
 
 and 66 percent
(137 evaluations) in South America.
 
67-71
 
 Prescribing
chloroquine monotherapy against this parasite in
any setting, except one in which its effectiveness has
recently been demonstrated, should be considered
irresponsible.
Resistance to chloroquine by 
 
P. vivax
 
 has
emerged, apparently having originated in New
Guinea, where failure rates now approach 100 per-
cent.
 
63
 
 In contrast, surveys in Thailand reveal uni-
formly sensitive vivax malaria (not shown in Fig.
1).
 
72
 
 Chloroquine-resistant 
 
P. vivax
 
 may be charac-
terized as endemic to the Indonesian archipelago,
especially in the east (including New Guinea), spo-
radic in the rest of Asia, and rare in South America.
 
73
 
sulfadoxine–pyrimethamine
 
Sulfadoxine–pyrimethamine, which has potent ef-
ficacy against chloroquine-resistant and pyrimeth-
amine-resistant 
 
P. falciparum,
 
 became available in
1971 and became the standard second-line therapy
against chloroquine-resistant falciparum malaria.
This combination acts synergistically against folate
synthesis, inhibiting dihydropteroate synthase and
dihydrofolate reductase. Although rare, idiosyn-
cratic allergic reactions have occurred among users
of sulfa drugs, sulfadoxine–pyrimethamine has oth-
erwise offered superior safety and tolerability, along
with the advantage of single-dose therapy. Howev-
er, resistance to sulfadoxine–pyrimethamine was
recognized at the Thai–Cambodian border in the
1960s, and failures occurred in refugee camps in
Thailand in the 1970s.
 
38
drug resistance
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The rates of parasitologic failure of treatment
with sulfadoxine–pyrimethamine in sub-Saharan
Africa were relatively high in southern regions of
holoendemic infection (>50 percent) and low else-
where (<5 percent, except in Cameroon, where the
rate of failure was 10 percent). The rates of clinical
treatment failure in sub-Saharan Africa were simi-
larly distributed (<5 percent in the west and 8 to 34
percent in the east and south).
 
8
 
 Studies in Southeast
Asia indicated that the rates of parasitologic failure
at day 7 and day 28 were 36 percent and 49 percent,
respectively.
 
74-79
 
 Good efficacy (80 percent) persist-
ed elsewhere — in southwestern Asia and on the
Horn of Africa, where no parasitologic failures were
reported among 362 evaluations
 
80,81
 
; in southern
Asia, where the failure rate was 18 percent (of 339
evaluations) by day 28
 
55-57
 
; and in South America,
where the failure rate was 9 percent (of 50 evalua-
tions) by day 7, 14 percent (of 42 evaluations) by
day 14, and 6 percent (of 119 evaluations) by day
28.
 
82-84
 
 The risk of resistance to sulfadoxine–pyri-
methamine is relatively high in Southeast Asia and
eastern Africa.
 
mefloquine
 
Mefloquine emerged as a successor to chloroquine
in the 1980s. Resistance appeared in regions at the
border between Thailand and Cambodia within a
few years, perhaps owing to widespread use of qui-
nine, to which it is structurally related.
 
38
 
 Resistance
in that border region remains high.
 
85
 
 However, in
nearby regions resistance to mefloquine remains
relatively low. Smithuis et al.
 
62
 
 reported that, of 75
patients, more than 90 percent in the region of the
western border of Myanmar (Burma) responded
to mefloquine (at a dose of 15 mg per kilogram of
body weight). In another study, of 79 patients hos-
pitalized in Bangkok and treated with mefloquine
(25 mg per kilogram), 68 (86 percent) remained
free of parasitemia after 28 days.
 
86 Similar efficacy
was observed in Bangladesh.56 However, a group
of Dutch marines in Cambodia who were receiving
mefloquine prophylaxis during the 1990s had high
attack rates of falciparum malaria.87 In contrast,
the protective efficacy of mefloquine among Indo-
nesian soldiers in western New Guinea — where
the efficacy of chloroquine against P. falciparum and
P. vivax approaches zero63 — was 100 percent.88
The risk of the prophylactic or therapeutic failure
of mefloquine in Southeast Asia appears to be low
outside the shared borders of Thailand, Myanmar,
and Cambodia.
Few studies have evaluated the effectiveness of
mefloquine against falciparum malaria in Africa. In
the mid-1990s, Lobel et al.89 examined mefloquine
prophylaxis among 140 Peace Corps volunteers who
were infected by P. falciparum. Poor adherence ex-
plained most of the infections, but in five cases the
resistance appeared to be genuine (i.e., parasitemia
was present with >620 ng of mefloquine per mil-
liter in plasma). Despite sporadic, well-documented
failures of mefloquine among travelers to Africa, the
drug remains effective there.
Studies conducted in coastal Peru and in the Am-
azon Basin among 153 subjects with P. falciparum
malaria who were receiving mefloquine (at a dose
of 15 mg per kilogram) revealed complete sensitiv-
ity.68,90,91 Despite occasional reports of resistance
in the Amazon basin, the available evidence shows
a low risk of resistance throughout South America.
Mefloquine has received adverse attention in the
media in recent years. The drug has been blamed for
suicides, homicides, and other personal tragedies
on the basis of anecdotal accounts, which, by their
* The predominant determinants, according to available data, are listed.
† The mutation is associated with increased sensitivity to this drug.
Table 3. Mutations in Plasmodium falciparum That Are Associated with Resistance to Antimalarial Drugs.
Gene Product Genetic Determinant* Drug
pfcrt Transporter Thr76 Chloroquine
pfmdr 1 Transporter Tyr86 Chloroquine, mefloquine, quinine, 
dihydroartemisinin†
Copy number Mefloquine, artesunate
dhps Dihydropteroate synthetase Gly437, Glu540, Gly581 Sulfadoxine
dhfr Dihydrofolate reductase Asn108, Arg59, Ile51, Leu164 Pyrimethamine
cytb Cytochrome b Ser268 Atovaquone
n engl j med 352;15 www.nejm.org april 14, 2005
The new england journal of medicine
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nature, cannot establish cause and effect. Well-con-
trolled trials consistently indicate that mefloquine
given as prophylaxis is as well tolerated as other an-
timalarial drugs.92 Nonetheless, the drug has been
linked with a higher risk of insomnia, fatigue, and
adverse neuropsychiatric effects (e.g., depression
and anger) than other antimalarial drugs.93-95 The
risk appears highest among women, especially
those taking the drug for the first time and those
with a low body-mass index.96
quinine
Jesuit priests in Peru in the 1500s learned from the
Incas that powder from the bark of the cinchona tree
relieved shivering with cold, and they supposed it
would also offer relief from the chills of malaria. Its
activity against the parasite, later shown to be due
to quinine, was unknown to them. Resistance to
quinine appears sporadically, and a moderate risk
of treatment failure appears to be limited to some
regions of Southeast Asia and New Guinea. Zalis et
al.97 suggested that there might be a link between
poor in vitro responses to quinine and diminished
clinical responsiveness in the Amazon basin, but
without supporting clinical data. Recent well-con-
trolled trials of quinine monotherapy showed vari-
able rates of efficacy against P. falciparum: 92 percent
in a group of 49 patients in Bangladesh,56 67 per-
cent among 54 patients in western Thailand,98
and 80 percent among 30 patients in a clinic in
Bangkok.99 A seven-day regimen was more than 95
percent efficacious in Venezuela100 and Equatorial
Guinea.101 Rare reports of failure of intravenous
quinine for the treatment of severe or complicated
malaria have appeared sporadically.102
Oral quinine is used to treat uncomplicated ma-
laria, generally over a period of three to seven days
in combination with another blood-stage schizonti-
cide, typically tetracycline or doxycycline. Although
one study of 86 patients in Thailand showed the
superiority of a seven-day regimen combined with
tetracycline (a 100 percent efficacy rate) as com-
pared with a five-day regimen combined with tet-
racycline (87 percent),103 studies performed else-
where have shown complete efficacy with shorter
regimens combining quinine, doxycycline, and
primaquine.88,104
Poor adherence carries a high risk of treatment
failure, particularly because quinine causes a syn-
drome of adverse effects known as cinchonism,
including primarily tinnitus, nausea, and vertigo.
A randomized trial in Thailand recorded a 71 per-
cent rate of adherence.11 However, in Cambodian
villages, the rate of compliance with the same regi-
men was far lower — 11 to 20 percent — even after
an intervention to raise awareness about the need
for compliance.105
primaquine
Developed during World War II, primaquine re-
mains the only licensed tissue-stage schizonticide
(Fig. 2) for the prevention of relapse after infec-
tion (standard therapy) or as presumptive therapy
against relapse after exposure to the risk of infection,
without evidence of infection (terminal prophylax-
is). Recently recommended for use as prophylax-
is,106 primaquine has a uniquely broad spectrum,
killing liver stages, asexual blood stages (of P. vivax31
but not P. falciparum107), and sexual blood stages.
In endemic regions, primaquine is widely used as a
gametocytocide to prevent infection of mosquitoes.
Despite more than 50 years of use in millions of
people per year, primaquine is still shrouded in con-
fusion and genuine mystery. At least four different
regimens, some prescribed for only one week and
others for as long as eight weeks, are aimed at the
same objective of preventing relapse.108 Three fac-
tors largely explain the lack of uniformity: first, the
reluctance of health care programs to accept thera-
py that has a duration of two weeks; second, per-
ceived issues of toxicity and tolerability; and third,
the use of a total dose, rather than a dosing sched-
ule, as the primary determinant of efficacy. How the
same total dose of a rapidly eliminated drug kills
organisms irrespective of whether it is delivered over
a period of 7, 14, or 56 days defies explanation.
Resistance is not fully understood either. Resis-
tance in asexual blood stages of P. vivax has long
been known109 but is of no clinical consequence.
Reports of resistance to tissue-stage schizonticidal
activity fail to consider or describe patients’ adher-
ence, to exclude the possibility of reinfection, or to
address the possible recrudescence of chloroquine-
resistant strains. Lack of evidence of resistance to
primaquine in liver stages probably reflects a heavy
burden of proof rather than an absence of resis-
tance.108
Combined therapies, which constitute a widely
practiced strategy in the treatment of diseases such
as leprosy, tuberculosis, and infection with the hu-
combined therapies 
against resistance
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man immunodeficiency virus and which have long
been known to be effective against malaria,110 have
rarely been used in its treatment until recently.111
The use of more than one agent successfully requires
separate mechanisms of action against the same
stage of the parasite. Thus, because both sulfadox-
ine and pyrimethamine are folate antagonists, they
would not be considered a combined therapy. Sim-
ilarly, combining a blood-stage schizonticide with
primaquine is not considered combined therapy,
because the drugs attack different stages of the par-
asite. The fixed combination of atovaquone–chlo-
roguanide, which affects mitochondrial electron
transport and folate metabolism in asexual blood
stages, represents true combination therapy.112
Combined antimalarial therapies include old
and new drugs — old drugs in new combinations
(chloroquine and sulfadoxine–pyrimethamine), an
old drug combined with a new drug (amodiaquine
and artesunate), and new drugs in combination
(lumefantrine and artemether).113,114 Combination
therapy that includes artemisinin appears to be
potent and particularly useful in endemic regions;
extracted from the weed Artemesia annua, the arte-
misinins (primarily artemether, artesunate, and di-
hydroartemisinin) were developed in China during
the 1960s.
The artemisinins act very rapidly, reducing par-
asitemia by a factor of 104 with each cycle. Thus, for
a parasite burden in the range of 1012, only three
cycles are required to abolish parasitemia. The ar-
temisinins are rapidly eliminated, and daily admin-
istration for a period of seven days (three cycles) is
required. Episodes of recrudescence follow briefer
regimens, but a seven-day regimen is considered to
be impractical. Therefore, treatment for a period of
three days with artemisinin combined with a slowly
eliminated companion blood-stage schizonticide
has been adopted. This three-day regimen of arte-
misinin reduces the parasite burden by a factor of
108 (leaving only 0.000001 percent of parasites
surviving to be abolished by mefloquine) (Fig. 3).
The artemisinins also exert activity against game-
tocytes, reducing the probability of transmission.
The use of combination therapies with artemisi-
nin does not preclude the onset of drug resistance,
particularly since patients may not take the medi-
cation as directed. Thus, the multiple doses needed
with such combined therapies (typically six doses
over a period of three days) represent an important
potential pitfall. The emergence of resistant strains
may already be in progress. In vitro studies indicate
Figure 3. Combination Therapies with Artemisinin 
Derivatives.
The figure illustrates the rationale behind the use of an 
artemisinin derivative combined with a slowly excreted 
drug such as mefloquine for therapy against falciparum 
malaria over a period of five weeks. Panel A shows plas-
ma levels of mefloquine (blue line) and relatively high 
levels of parasitemia caused by strains resistant to 
mefloquine (solid red line) and sensitive to mefloquine 
(dashed red line). Prescribed therapy eliminates the sen-
sitive but not the resistant infection. Panel B shows the 
importance of parasite burden as a determinant of drug 
effectiveness, indicating the elimination of both sensitive 
and resistant infections at lower levels of burden. Panel C 
shows the quick inhibitory effect of a short regimen of an 
artemisinin derivative (black line), but, owing to its short 
plasma half-life, the drug cannot completely eradicate the 
parasite. Panel D shows the effect of combining an arte-
misinin derivative (black line) with a drug such as meflo-
quine (blue line): a quick “knockdown” of the parasite 
burden by the artemisinin derivative allows the slower-
acting and more slowly excreted mefloquine to exert ac-
tivity against a greatly diminished parasite burden.
Mefloquine
Mefloquine-
resistant
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diminished susceptibility to artesunate among
Asian isolates.41 Isolates from western Cambodia,
where combination therapies with artemisinin de-
rivatives are widely used, show diminished suscep-
tibility to the combination of mefloquine and artes-
unate, as compared with isolates from eastern
Cambodia.115 In contrast, in the 1990s in some re-
gions bordering western Thailand, combination
therapies with artemisinin derivatives were de-
ployed as first-line therapy with excellent efficacy
(more than 90 percent), and this success appears to
be stable.116 Where more resources are available,
including medications, resistant strains have been
slower to develop. Where both medication and an
effective health care infrastructure are present, re-
sistance can be controlled. Such economic and
personnel issues may explain the contrasting find-
ings with regard to rates of resistance to combina-
tion therapies with artemisinin derivatives.117 Thus,
supplying these therapies in the setting of an ade-
quate health care infrastructure would seem the best
way to prevent the onset of resistance.
Patients with severe or complicated malaria of-
ten cannot take oral medication, and parenteral
quinine has been the standard approach to therapy.
Rectal artesunate may radically improve the care of
such patients, especially across the geographic ex-
panses of regions of endemic infection where par-
enteral medications are neither available nor prac-
tical. Clinical trials indicated that rectal artesunate
(combined with another blood-stage schizonticide)
cleared parasitemia more quickly than parenteral
quinine and with equal efficacy.118,119
A global public health threat due to the resurgence
of malaria stems from a general collapse of vector-
control operations and from resistance to chloro-
quine or sulfadoxine–pyrimethamine. Recent sur-
veys show rates of treatment failure higher than 50
percent for chloroquine in most affected regions,
as well as poor efficacy of sulfadoxine–pyrimetha-
mine in sub-Saharan Africa and Southeast Asia.
Quinine and mefloquine remain effective therapies
everywhere except in some regions bordering Thai-
land. Resistance to primaquine — the only drug for
preventing relapse — probably occurs but has not
yet been confirmed. New drugs should be effective
among the poor, self-treating rural populations in
regions of endemic disease and should be provided
through programs that address issues of availabili-
ty and cost, convenience and adherence, safety and
tolerability, and quality assurance. The combination
therapies with artemisinin derivatives represent the
present best efforts toward providing such thera-
peutic agents. These drugs deliver an inhibitory
effect that substantially reduces the probability of
selection for resistant parasites, as compared with
traditional monotherapies. However, widespread
distribution without complementary capabilities in
the delivery of health care places the clinical useful-
ness of these critical drugs in doubt.
The views expressed here are those of the author and do not nec-
essarily reflect or represent those of the U.S. Navy or the Department
of Defense.
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